NCT07642024

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2026-06Est. Completion: 2032-12

Enrollment target: 90 participants

Locations

Shanghai East Hospital, Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality, China

Contact

Sa Xiao, PHDxiaosa@baili-pharm.com 15013238943

Other microbiome trials you might be interested in

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerPhase 3Recruiting

Recurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma

This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) …

Anchorage, United StatesEst. completion Dec 31, 2028

View Trial →

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCPhase 2Recruiting

Non Small Cell Lung Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.